0
DiscoverMap the risk surface
Find where AI, vendor tools, data flows, and cybersecurity exposure already touch regulated work before the organization scales around unknown risk.
Governance & Risk
Govern AI before risk governs you.
Life sciences teams are adopting AI through platforms, vendors, copilots, agents, and business-led pilots. USDM helps turn that pressure into a governed operating model: clear ownership, risk-based controls, cybersecurity alignment, third-party oversight, validation discipline, and evidence your teams can defend.
Risk reality
The governance perimeter moved.
Business teams using public or embedded AI before formal approval exists
Vendors adding AI features without clear regulated-use boundaries
Cybersecurity, Quality, Regulatory, IT, and Procurement reviewing risk in separate lanes
Policies that describe responsible AI but do not create workflow-level evidence
The answer is not a policy binder. It is a working governance system that connects AI, cybersecurity, vendor oversight, data, validation, and business accountability.
Layer 0–5 governance strategy
Build governance in layers, not after the mess arrives.
USDM uses a layered AI operating model to move organizations from visibility to control to scale. Governance is not a separate workstream sitting beside AI. It is the structure that lets AI, cybersecurity, vendor oversight, data integrity, and regulated workflows operate together.
1
ControlSet governance guardrails
Define intended use, ownership, policy, risk classification, approval paths, and escalation rules so teams can move without improvising controls.
2
PrepareMake systems and vendors governable
Align cybersecurity, platform access, third-party oversight, data lineage, and evidence expectations around the workflows AI will affect.
3
OperateEmbed controls into workflows
Turn policy into review gates, human accountability, audit trails, monitoring, vendor controls, and change discipline inside daily operations.
4
DefendGenerate evidence as work happens
Create inspectable records for decisions, approvals, exceptions, supplier reviews, model changes, access changes, and control performance.
5
ScaleContinuously govern the portfolio
Monitor drift, incidents, new use cases, vendor changes, cybersecurity signals, adoption, and control effectiveness as the AI portfolio grows.
The governance system
The work is visibility, ownership, controls, and evidence.
Strong governance gives teams a way to say yes safely. It creates the pathway for high-value AI and automation while making risk visible enough to manage across Quality, Regulatory, Clinical, Manufacturing, IT, Security, Procurement, Legal, and executive leadership.
Inventory + intended use
Create a living view of AI use cases, third-party tools, system touchpoints, regulated impact, and business ownership.
Risk classification
Segment use cases by GxP impact, data sensitivity, decision criticality, automation level, vendor dependency, and cybersecurity exposure.
Accountable operating model
Clarify who approves, who operates, who reviews, who owns exceptions, and when Quality, Regulatory, Security, Legal, and business leaders engage.
Evidence architecture
Define the artifacts, audit trails, review records, validation evidence, vendor records, and monitoring signals needed to defend use over time.
Control areas
One governance architecture across AI, cybersecurity, vendors, and validation.
The risk does not arrive neatly by department. USDM helps connect the controls so the organization can govern the full operating environment, not just one policy domain at a time.
AI governance
Policies, SOPs, risk tiers, human oversight, approved-use boundaries, training expectations, and workflow controls for responsible adoption.
Cybersecurity
Secure-by-design practices, access governance, vulnerability management, incident readiness, platform oversight, and FDA-aligned cybersecurity evidence.
Third-party risk
Vendor AI disclosure, supplier risk segmentation, continuous monitoring, contract/control alignment, and defensible oversight of partner ecosystems.
Validation + change control
Risk-based validation scope, CSA/CSV alignment where appropriate, release discipline, model/vendor change review, and lifecycle documentation.
What changes for the business
Governance becomes the path to AI value, not the department of no.
The point is not to slow AI down. The point is to make the highest-value use cases safe enough, clear enough, and evidence-backed enough to scale. That means fewer hidden pilots, fewer vendor surprises, better inspection readiness, and more confidence from the teams expected to use the technology.
Clear visibility into AI, vendor, cybersecurity, and regulated workflow risk
Controls that support adoption instead of freezing the business
Evidence trails that Quality, Security, Regulatory, and executive teams can review
A scalable operating model for governed AI across domains and platforms
Deep dives
Keep going where the risk is highest.
White Paper and GuideSee proof See proof
AI Governance for Life Sciences: The Enterprise Framework for Compliant, Scalable AI
AI governance for life sciences. FDA and EU AI Act readiness, GxP validated systems, and ISO 42001 guidance for compliant, scalable AI.
Read BlogModernizing TPRM for an AI-Driven Ecosystem: What Good Looks Like in 2026
Life sciences must modernize TPRM to safely scale AI and cloud tech. Discover 2026-ready risk strategies that enable innovation, compliance, and trust.
ReadAI deploymentGovernance
Transforming Third-Party Vendor Risk Management at Enterprise Scale
Discover how global biopharma transformed third-party risk management (TPRM) with USDM's continuous monitoring, cutting assessment times by 60%.
Assessment speed
60% reduction
AI deploymentGovernance
User-Level Performance Metrics Help Evaluate Retraining and Staffing Needs
Life sciences organization running Veeva Vault CDMS across multiple clinical trial sites
Discover how USDM's Veeva Vault optimization and advisory services helped a life sciences customer leverage CDMS audit trail analytics to improve clinical site performance, reduce data entry delays, and establish ongoing platform governance.
Performance visibility
User-level CDMS metrics
Frequently Asked Questions
Questions leaders ask before they move.
Why does AI governance matter in life sciences?
AI governance matters because life sciences organizations cannot afford unmanaged adoption in regulated environments. Governance aligns innovation with compliance, accountability, operational control, inspection readiness, and data integrity.
What are the biggest AI risks life sciences companies need to manage?
The biggest risks include ungoverned adoption, weak validation strategy, poor platform quality, hidden third-party AI use, and limited visibility into whether AI investments are performing as intended.
How should leaders think about third-party AI risk?
Third-party AI risk should be treated as a governance issue, not just a vendor issue. Oversight must extend to CROs, software providers, and service partners where hidden AI use can affect regulated processes.
Why is platform readiness critical before enabling AI?
AI capabilities are only as strong as the platforms and data environments underneath them. Poorly configured or inconsistently adopted systems make AI outputs less reliable and less defensible.
How does FDA cybersecurity guidance raise the bar for governance?
FDA cybersecurity guidance reinforces that cybersecurity is part of the broader governance structure required to protect data, maintain product quality, support patient safety, and demonstrate control as technologies evolve.
What does strong AI governance and risk management look like in practice?
Strong governance creates visibility, accountability, and measurable control across AI, cybersecurity, and third-party risk. It defines where AI is used, how risk is assessed, what controls are required, and how effectiveness is monitored.
Do we know which vendors create the highest regulatory, operational, or cyber risk?
A mature TPRM program starts by inventorying third parties and linking them to business criticality so the highest-risk vendors are visible, tiered, and managed with the right level of oversight.
Are we relying on annual reviews for vendors whose posture can change monthly?
Annual questionnaires are too slow for vendors that change continuously. Mature programs use continuous monitoring, standardized intake and renewal workflows, and ongoing signal review instead of a once-a-year snapshot.
Can we show evidence of oversight for inspectors, auditors, or executive stakeholders?
Effective vendor oversight includes clear ownership, standardized assessment criteria, risk-tiered workflows, and executive reporting that translates vendor risk into business impact and defensible evidence.
Do our current processes account for AI-enabled vendors and cloud-native delivery models?
They should. Modern TPRM has to account for vendor AI features, cloud-native architectures, change velocity, API exposure, and fourth-party dependencies, not just static policy documents.
How should teams respond to FDA Cybersecurity Guidance?
Start with an honest assessment of maturity, identify the products, systems, and processes under evolving cyber expectations, trace evidence from architecture to validation to regulatory documentation, and define ownership for monitoring and response after release.
Talk to a risk specialist
Build governance that holds up under scrutiny.
USDM helps regulated organizations design risk frameworks, manage third-party vendors, and maintain cybersecurity postures that satisfy regulators and auditors.
- Third-party risk management and vendor qualification
- vCISO and cybersecurity services for life sciences
- GxP audit readiness and remediation
- Risk-based governance frameworks